Based on the information provided in the press release, BrainStormâŻCellâŻTherapeuticsâŻInc. (OTCQB:âŻBCLI) is only announcing that it will hold a conference call on AugustâŻ14,âŻ2025 to discuss its secondâquarter financial results and give a corporate update.
The excerpt you shared does not contain any details about revised financial guidance, forecasts, or outlook for the upcoming quarters. It simply states that the call will be used to present the results and provide a corporate update; any specific forwardâlooking guidance would presumably be disclosed during the call itself, not in this announcement.
In short: No â the news release does not include any updated guidance or outlook for future quarters.
Other Questions About This News
Are there any new partnership or licensing agreements disclosed?
What is the status of the company's lead clinical programs and any trial updates?
How does the cash position and burn rate compare to previous periods?
How does the updated financial performance compare to consensus analyst estimates?
What is the anticipated impact of the corporate update on BCLI's valuation?
What are the potential risks highlighted in the call that could affect the stock?
How does BCLI's performance and pipeline progress compare to peers in the stem cell space?
Did the company address any regulatory milestones or FDA interactions?
What are the revenue and earnings expectations for Q2 and the full year?
Did the company discuss any upcoming milestones that could drive shortâterm price movement?
Are there any changes in the capital allocation strategy or upcoming financing needs?